Last updated on April 2019

Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Diabetic Nephropathy
  • Age: Between 30 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

Additional criteria check may apply for qualification:

  • Glycated hemoglobin(HbA1c) of 6.5% and 12.0%
  • eGFR of 30 mL/min/1.73m2 and <90 mL/min/1.73m2
  • The median UACR of the first morning void urine samples is 300 mg/g Cr and 5000 mg/g Cr
  • Patients who are taking on angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB)
  • Patients who are under dietary management and taking therapeutic exercise for diabetes

Exclusion Criteria:

Additional criteria check may apply for qualification:

  • Type I diabetes, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes
  • A diagnosis of non-diabetic renal disease
  • Hereditary glucose-galactose malabsorption or primary renal glucosuria
  • Class IV heart failure symptoms according to New York Heart Association (NYHA) functional classification
  • Severe hepatic disorder or severe renal disorder
  • Blood potassium level >5.5 mmoL/L
  • Stable blood pressure (diastolic blood pressure (DBP) 180mmHg or systolic blood pressure (SBP) 100mmHg)

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.